Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 52
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.
Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, Wu PH, Gu YK. Zhang TQ, et al. Signal Transduct Target Ther. 2023 Oct 27;8(1):413. doi: 10.1038/s41392-023-01663-6. Signal Transduct Target Ther. 2023. PMID: 37884523 Free PMC article. Clinical Trial.
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qiao Q, Han C, Ye S, Li J, Shao G, Bai Y, Xu A, Sun M, Wang W, Wu J, Huang M, Song L, Huang L, Liu T, Liu W, Wang ZM, Li B, Xia M, Bai L. Qiao Q, et al. Front Immunol. 2023 Oct 24;14:1238667. doi: 10.3389/fimmu.2023.1238667. eCollection 2023. Front Immunol. 2023. PMID: 37942328 Free PMC article. Clinical Trial.
Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski S, Wei AC, Tu D, O'Callaghan CJ. Chen EX, et al. JAMA Netw Open. 2023 Dec 1;6(12):e2346094. doi: 10.1001/jamanetworkopen.2023.46094. JAMA Netw Open. 2023. PMID: 38051531 Free PMC article. Clinical Trial.
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.
Cho Y, Choi JW, Kwon H, Kim KY, Lee BC, Chu HH, Lee DH, Lee HA, Kim GM, Oh JS, Hyun D, Lee IJ, Rhim H; Research Committee of the Korean Liver Cancer Association. Cho Y, et al. Clin Mol Hepatol. 2023 Jul;29(3):521-541. doi: 10.3350/cmh.2023.0202. Epub 2023 Jul 1. Clin Mol Hepatol. 2023. PMID: 37482892 Free PMC article.
76 results